CF PharmTech repurchases 9,500 H-shares; outstanding share count slips 0.0031%

Bulletin Express03-31

CF PharmTech, Inc. disclosed a small-scale share buyback executed on 31 March 2026. The company repurchased 9,500 H-shares on the Hong Kong Stock Exchange at prices ranging between HK$22.90 and HK$23.22, translating to a volume-weighted average cost of HK$22.9989 per share and a total cash outlay of HK$0.22 million.

The transaction reduced the number of issued shares (excluding treasury stock) to 301.72 million, down 0.0031% from the level reported on 28 February 2026. Treasury shares rose to 506,000, while the overall issued share count remained unchanged at 302.22 million because the repurchased shares have been retained in treasury rather than cancelled.

The buyback forms part of the mandate approved on 16 December 2025, which authorises the repurchase of up to 30.22 million shares. To date, the company has repurchased 506,000 shares under this authority, equivalent to 0.17% of the issued shares outstanding on the mandate date.

Under Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or disposing of treasury shares until 30 April 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103936432?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103936432","market":"us","top_or_hot":-1,"title":"CF PharmTech repurchases 9,500 H-shares; outstanding share count slips 0.0031%","media":"Bulletin Express","content":"<p>CF PharmTech, Inc. disclosed a small-scale share buyback executed on 31 March 2026. The company repurchased 9,500 H-shares on the Hong Kong Stock Exchange at prices ranging between HK$22.90 and HK$23.22, translating to a volume-weighted average cost of HK$22.9989 per share and a total cash outlay of HK$0.22 million.</p>\n<p>The transaction reduced the number of issued shares (excluding treasury stock) to 301.72 million, down 0.0031% from the level reported on 28 February 2026. Treasury shares rose to 506,000, while the overall issued share count remained unchanged at 302.22 million because the repurchased shares have been retained in treasury rather than cancelled.</p>\n<p>The buyback forms part of the mandate approved on 16 December 2025, which authorises the repurchase of up to 30.22 million shares. To date, the company has repurchased 506,000 shares under this authority, equivalent to 0.17% of the issued shares outstanding on the mandate date.</p>\n<p>Under Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or disposing of treasury shares until 30 April 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech repurchases 9,500 H-shares; outstanding share count slips 0.0031%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech repurchases 9,500 H-shares; outstanding share count slips 0.0031%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-31 18:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PharmTech, Inc. disclosed a small-scale share buyback executed on 31 March 2026. The company repurchased 9,500 H-shares on the Hong Kong Stock Exchange at prices ranging between HK$22.90 and HK$23.22, translating to a volume-weighted average cost of HK$22.9989 per share and a total cash outlay of HK$0.22 million.</p>\n<p>The transaction reduced the number of issued shares (excluding treasury stock) to 301.72 million, down 0.0031% from the level reported on 28 February 2026. Treasury shares rose to 506,000, while the overall issued share count remained unchanged at 302.22 million because the repurchased shares have been retained in treasury rather than cancelled.</p>\n<p>The buyback forms part of the mandate approved on 16 December 2025, which authorises the repurchase of up to 30.22 million shares. To date, the company has repurchased 506,000 shares under this authority, equivalent to 0.17% of the issued shares outstanding on the mandate date.</p>\n<p>Under Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or disposing of treasury shares until 30 April 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1103936432","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103936432","pubTimestamp":1774953888,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CF PharmTech, Inc. disclosed a small-scale share buyback executed on 31 March 2026. The company repurchased 9,500 H-shares on the Hong Kong Stock Exchange at prices ranging between HK$22.90 and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PharmTech回购9,500股H股；流通股数量下滑0.0031%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PharmTech, Inc. disclosed a small-scale share buyback executed on 31 March 2026. The company repurchased 9,500 H-shares on the Hong Kong Stock Exchange at prices ranging between HK$22.90 and HK$23.22, translating to a volume-weighted average cost of HK$22.9989 per share and a total cash outlay of HK$0.22 million.\nThe transaction reduced the number of issued shares (excluding treasury stock) to 301.72 million, down 0.0031% from the level reported on 28 February 2026. Treasury shares rose to 506,000, while the overall issued share count remained unchanged at 302.22 million because the repurchased shares have been retained in treasury rather than cancelled.\nThe buyback forms part of the mandate approved on 16 December 2025, which authorises the repurchase of up to 30.22 million shares. To date, the company has repurchased 506,000 shares under this authority, equivalent to 0.17% of the issued shares outstanding on the mandate date.\nUnder Hong Kong listing rules, CF PharmTech is restricted from issuing new shares or disposing of treasury shares until 30 April 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103936432","isCrawlerRequest":true}